Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | April 2009 |
| End Date: | March 2020 |
A Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
The maximum tolerated dose of 3-session (ie, treatment) stereotactic radiosurgery to treat
brain metastases greater than 4.2 cm3 in size will be determined.
This study investigates if increasing radiation dose improves outcome for patients without
greater toxicity (side effects).
brain metastases greater than 4.2 cm3 in size will be determined.
This study investigates if increasing radiation dose improves outcome for patients without
greater toxicity (side effects).
Inclusion Criteria:
- Age 18 years and older with pathologically-proven solid tumor malignancy and 1 to 4
brain metastases, one of which is 4.2 to 33.5 cm^3.
- Systemic therapy: Prior cytoxic systemic therapy must be completed ≥ 5 days prior to
radiosurgery. No concurrent cytoxic systemic therapy along with SRS. Cytoxic systemic
therapy to start ≥ 5 days after the completion of SRS.
- Prior surgery or SRS is allowed as long as the target metastatic lesion in this study
has not previously been treated with SRS.
- Ability to understand and the willingness to sign a written informed consent.
- Life expectancy of ≥ 12 weeks.
Exclusion Criteria:
- Previously treated with whole brain irradiation
- Metastatic lesion in question has previously been treated with SRS.
- > 4 total brain metastases at the time of initial evaluation.
- Pediatric patients (age < 18), pregnant women, and those who are unable to give
informed consent.
We found this trial at
1
site
Stanford University School of Medicine Vast in both its physical scale and its impact on...
Click here to add this to my saved trials
